H0262
HAT Media Supplement (50×) Hybri-Max™
lyophilized powder, suitable for hybridoma, BioXtra
Synonym(s):
HAT Supplement, Hypoxanthine-Aminopterin-Thymidin (HAT) media supplement
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352207
NACRES:
NA.75
Product Name
HAT Media Supplement (50×) Hybri-Max™, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma
Quality Level
sterility
γ-irradiated
product line
BioXtra
form
lyophilized powder
technique(s)
cell culture | hybridoma: suitable
impurities
endotoxin, tested
shipped in
dry ice
storage temp.
−20°C
Application
HAT Media Supplement (50×) Hybri-Max™ has been used:
- in the selection and validation of hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient clones
- in the generation of mAbs (monoclonal antibodies)
- in the luciferase-based bioassay (LUC) assay
Preparation Note
Reconstitute contents of vial with 10 ml sterile cell culture medium. Stock solution is sufficient to prepare 500 ml medium. Final working concentration: 100 μM hypoxanthine, 0.4 μM aminopterin, 16 μM thymidine.
Legal Information
Hybri-Max is a trademark of Sigma-Aldrich Co. LLC
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P2 (EN 143) respirator cartridges
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Product Information Sheet
J H Connolly et al.
Journal of anatomy, 195 ( Pt 2), 161-171 (1999-10-21)
The gross and histological appearance and the distribution of T and B lymphocytes and plasma cells are described for lymphoid tissues obtained from 15 platypuses. The spleen was bilobed and surrounded by a thick capsule of collagen, elastic fibres and
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta
Hermanrud C, et al.
Journal of Immunological Methods, 1-9 (2016)
Youngkyun Kim et al.
Clinical & translational immunology, 4(11), e51-e51 (2015-12-19)
This study was undertaken to develop a novel anti-citrullinated peptide antibody (ACPA) and to investigate its arthritogenicity in a collagen-induced arthritis (CIA) model. The novel ACPA, 12G1, was developed by injecting cyclic citrullinated antigen in mice and subsequently hybridizing the